Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma (NCT05226494)
A Phase 1 Trial to Evaluate the Safety and Tolerability of Fb-PMT in Patients With Recurrent Glioblastoma
🩺 Plain-English Summary (8th-Grade Level)
Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the brain. This study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma.
Who can join: Review the eligibility criteria below.
Location: Smilow Cancer Hospital — New Haven, Connecticut
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Smilow Cancer Hospital — New Haven, Connecticut
📞 Contact the Study Coordinator
Phone: (203) 260-9632
Email: amy.rodrigues@yale.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Glioma, Malignant
- ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM — Durham, North Carolina
- Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma — New York, New York
- Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma — Durham, North Carolina
- Window of Opportunity Study of DSP-0390 in Gliomas — St Louis, Missouri
Explore by condition: All Glioma, Malignant clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.